University of Michigan COPD Identification Through Lung Cancer Screening Cohort Study - MAP2

Exclusion Criteria14

• The presence of a respiratory condition other than COPD or asthma, or of a comorbid condition that in the judgment of the investigator may be the principal cause of respiratory symptoms (e.g. dyspnea or decreased exercise tolerance).
• Severe asthma, which is defined as any of the following:
• Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS/LABA or high dose ICS or add-on LAMA; Medium dose = \>250 fluticasone propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). We will accept low-dose ICS/LABA or medium dose ICS.
• or 3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months or One asthma hospitalization in the past 12 months
• Concurrent participation in a therapeutic trial where treatment is blinded.
• Active pregnancy. Documentation of birth control will be required for pre-menopausal women.
• Cognitive dysfunction that prevents the participant from completing study procedures.
• BMI \> 35 kg/m2 at baseline, due to the effects of body weight on CT scan quality.
• Current illicit substance abuse, including cannabis smoking.
• Any illness expected to cause mortality in the next 3 years.
• Any implanted metallic devices or prosthesis above the waist that could degrade thoracic CT scan quality.
• History of thoracic radiation or thoracic surgery with resection of lung tissue.
• Participants who present with an acute exacerbation of COPD, either solely participant-identified or that has been clinically treated, in the last 30 days can be rescreened for the study once the 30-day window from end of drug therapy has passed.
• Participants who present with current use of acute antibiotics or steroids can be rescreened for the study ≥30 days after discontinuing acute antibiotics/steroids. This restriction does not apply to participants who are on chronic prednisone therapy of \<10 mg per day or \<20 mg every other day or participants who are currently on chronic, prophylactic, or suppressive antibiotic therapy.